Current Status of Ozempic Litigation The Ozempic litigation has grown into one of the largest pharmaceutical mass torts in recent history, with numerous Ozempic lawsuits and case numbers accelerating rapidly throughout 2025 as more patients discover connections between their injuries and GLP-1 medications
A 4 mg maintenance dose is also being studied alongside 9 mg and 12 mg
As a peptide supplier with certificate of analysis , we are the go-to Peptide Sciences alternative trusted by the research community
Location: Indianapolis, IndianaWarning Letter Date: September 9, 2025FDA Department Issuing Warning: Center for Drug Evaluation and Research (CDER)Type of Warning: False & Misleading Claims/Misbranded DrugsSubject of Violation: An Oprah Special: Shame, Blame, and the Weight Loss Revolution, regarding Zepbound (tirzepatide) and Mounjaro (tirzepatide)FDA Warning: In the program, which aired on television in 2024 and until recently was available continuously on the ABC website and through various streaming services, Eli Lilly promoted Mounjaro and Zepbound in a manner that failed to present the serious risks of these drug products in a truthful and nonmisleading manner, despite FDAs prior correspondence (advisory comments dated June 13, 2022 and June 21, 2022)
